The aim of this work was an experimental and clinical study of increasing of the efficiency of therapy of respiratory tuberculosis with drug resistant pathogen by including a combination of anti-tuberculosis drugs of new generation - Bedaquiline (Bq) and Thioureidoiminomethylpyridi-nium perchlorate (perchlozone, Tpp) into treatment regimens. The presented results were obtained: in the experiment on a model of tuberculosis infection in 103 male C57black / 6 mice, reproduced by inserting into the lateral vein of the tail of a suspense of clinical strains of Mycobacterium tuberculosis with multi-drug resistance (MDR) and with various combinations of mutations in the genes; in the clinic - on the basis of examination and treatment of 148 patients with multidrug-resistant respiratory tuberculosis. It is shown that the application of the therapy schemes for multiple and broad drug resistant tuberculosis, containing Bq and Tpp in combination with drugs, selected taking into account the drug sensitivity of mycobacter
Original languageRussian
Pages (from-to)115-121
JournalОБЗОРЫ ПО КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИ И ЛЕКАРСТВЕННОЙ ТЕРАПИИ
Volume18
Issue number2
StatePublished - 2020

    Research areas

  • bedaquiline, clinical efficacy, drug resistance of pathogen, Preclinical evaluation, Thioureidoiminomethylpyridinium perchlorate, treatment, tuberculosis, undesirable phenomena, бедаквилин, доклиническая оценка, клиническая эффективность, лекарственная устойчивость возбудителя, лечение, нежелательные явления, тиоуреидоиминометилпиридиния перхлорат, туберкулез

ID: 78514457